CIA
NBIX icon

Cape Investment Advisory’s Neurocrine Biosciences NBIX Stock Holding History

Cape Investment Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.07K Buy
+36
New +$5.34K ﹤0.01% 977
2026
Q1 		– Sell
-35
Closed -$4.96K – 834
2025
Q4 		$4.96K Hold
35
– – ﹤0.01% 909
2025
Q3 		$4.91K Hold
35
– – ﹤0.01% 525
2025
Q2 		$4.4K Buy
+35
New +$4.01K ﹤0.01% 791
2024
Q1 		– Sell
-20
Closed -$2.63K – 1088
2023
Q4 		$2.63K Buy
+20
New +$2.3K ﹤0.01% 893

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cape Investment Advisory's NBIX Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 36 shares worth $6.07K. The stake represents ﹤0.01% of the portfolio and ranks #977 among its holdings. This is a return to the name: Cape Investment Advisory previously reported a position in NBIX as recently as Q4 2025.

Cape Investment Advisory first reported a position in NBIX in Q4 2023 and has held it in 5 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Cape Investment Advisory held 36 shares of Neurocrine Biosciences worth $6.07K as of Q2 2026.
  • Neurocrine Biosciences was a new Cape Investment Advisory position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Cape Investment Advisory's portfolio in Q2 2026, its #977 holding.
  • Cape Investment Advisory first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 5 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.